Relay Therapeutics (NASDAQ:RLAY) Insider Sells $41,630.57 in Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) insider Donald Bergstrom sold 2,237 shares of the business’s stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $18.61, for a total transaction of $41,630.57. Following the completion of the sale, the insider owned 407,660 shares in the company, valued at $7,586,552.60. This represents a 0.55% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Relay Therapeutics Stock Down 3.2%

Relay Therapeutics stock opened at $18.83 on Friday. Relay Therapeutics, Inc. has a 52-week low of $3.03 and a 52-week high of $20.79. The firm’s fifty day moving average is $17.16 and its 200 day moving average is $13.07. The company has a market cap of $3.61 billion, a price-to-earnings ratio of -11.99 and a beta of 1.67.

Relay Therapeutics (NASDAQ:RLAY) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.06). The business had revenue of $3.00 million for the quarter, compared to analyst estimates of $5.58 million. On average, equities research analysts anticipate that Relay Therapeutics, Inc. will post -1.57 earnings per share for the current fiscal year.

Institutional Trading of Relay Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Torren Management LLC purchased a new position in shares of Relay Therapeutics during the fourth quarter valued at approximately $30,000. KBC Group NV bought a new position in shares of Relay Therapeutics during the first quarter valued at approximately $34,000. Smartleaf Asset Management LLC raised its holdings in shares of Relay Therapeutics by 288.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 4,426 shares of the company’s stock worth $37,000 after buying an additional 3,287 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Relay Therapeutics in the fourth quarter worth approximately $46,000. Finally, Captrust Financial Advisors bought a new stake in shares of Relay Therapeutics during the 2nd quarter worth approximately $49,000. 96.98% of the stock is owned by hedge funds and other institutional investors.

Relay Therapeutics News Roundup

Here are the key news stories impacting Relay Therapeutics this week:

• Positive Sentiment: Potential earnings catalyst: Zacks expects Relay Therapeutics could exceed consensus expectations in its upcoming quarterly report, which may support near-term investor sentiment. This is only an earnings preview, not a reported result. Relay Therapeutics Expected to Beat Earnings Estimates
• Positive Sentiment: Breast cancer program draws renewed interest: Coverage says Relay’s breast cancer program has revitalized the investment story, potentially expanding the company’s opportunity in oncology. Relay Therapeutics Revitalized by Breast Cancer Program
• Positive Sentiment: Institutional ownership and analyst support remain strong: Several funds increased their positions during the first quarter, and recent analyst targets generally imply additional upside. MarketBeat reports a “Moderate Buy” consensus rating with an average target of $24.92.
• Neutral Sentiment: Second-quarter results are scheduled for August 6: Relay will report financial results and corporate updates after the market close. Investors will likely focus on pipeline progress, cash resources and development plans. Relay Therapeutics Second-Quarter Results Announcement
• Neutral Sentiment: Insider selling was administrative: CFO Thomas Catinazzo and insiders Donald Bergstrom and Peter Rahmer sold a combined 4,444 shares at $18.61 to cover tax withholding on vested equity awards. Each retained substantial holdings, limiting the bearish significance of the transactions. Relay Therapeutics Insider Transactions
• Negative Sentiment: Competition and clinical risk remain material: Relay is still a clinical-stage biotechnology company, and its valuation depends heavily on successful trials and eventual commercialization. Intense competition in breast cancer could limit the program’s upside.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on RLAY. Oppenheimer boosted their price objective on Relay Therapeutics from $14.00 to $18.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 28th. Guggenheim raised their price objective on Relay Therapeutics from $22.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, May 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Relay Therapeutics in a report on Monday, July 6th. Barclays boosted their target price on Relay Therapeutics from $21.00 to $27.00 and gave the company an “overweight” rating in a research report on Wednesday, May 20th. Finally, Citigroup restated an “outperform” rating on shares of Relay Therapeutics in a research report on Wednesday, May 20th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $24.92.

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.